Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ulixertinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Strata Oncology
Deal Size : Undisclosed
Deal Type : Partnership
Details : Partnership aims to accelerate patient identification and enrollment for BioMed Valley's Phase 2 study of BVD-523 (ulixertinib) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (non-BRAF V600E mutations).
Brand Name : BVD-523
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 29, 2020
Lead Product(s) : Ulixertinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Strata Oncology
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?